Clinical Trials Directory

Trials / Conditions / Chronic Lymphoid Leukemia

Chronic Lymphoid Leukemia

11 registered clinical trials studyying Chronic Lymphoid Leukemia — 1 currently recruiting.

StatusTrialSponsorPhase
UnknownEvaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia
NCT05350826
University Hospital, ToulouseN/A
CompletedEfficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
NCT04883749
German CLL Study GroupPhase 2
Active Not RecruitingIbrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus
NCT04608318
German CLL Study GroupPhase 3
Active Not RecruitingSequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (A
NCT04515238
German CLL Study GroupPhase 2
TerminatedThe Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated
NCT03804372
Gruppo Italiano Malattie EMatologiche dell'AdultoPhase 2
Active Not RecruitingPreemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
NCT03766763
French Innovative Leukemia OrganisationPhase 2
RecruitingAllogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red
NCT03852407
University of LiegePhase 2
CompletedSequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients
NCT03787264
German CLL Study GroupPhase 2
TerminatedThe Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
NCT01518959
Semmelweis UniversityPhase 3
CompletedSafety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
NCT00788684
AbbViePhase 1
CompletedA Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT00406809
AbbVie (prior sponsor, Abbott)Phase 1 / Phase 2